Literature DB >> 11085870

Inhibition of Huntington synthesis by antisense oligodeoxynucleotides.

C Nellemann1, K Abell, A Nørremølle, T Løkkegaard, B Naver, C Röpke, J Rygaard, S A Sørensen, L Hasholt.   

Abstract

The Huntington disease gone encodes the protein huntington, which is widely expressed during embryonic development and in mature tissues. In order to elucidate the physiological function of huntington, which so far is unknown, we intend to study the effect of antisense down-regulated huntington expression. We have found an inhibiting effect of a phosphorothioated oligodeoxynucleotide (PS-ODN) added to the culture medium of embryonic teratocarcinoma cells (NT2) and postmitotic neurons (NT2N neurons) differentiated from the NT2 cells. Specific inhibition of expression of endogenous huntington was achieved in NT2N neurons in the concentration range of 1-5 microM PS-ODN, whereas no inhibition was obtained in NT2 cells. We describe in detail the selection of the target sequence for the antisense oligo and the uptake, intracellular distribution, and stability of the antisense PS-ODN in the two cell types. Antisense down-regulation of huntington in this model of human neurons represents a suitable approach to study its normal function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085870     DOI: 10.1006/mcne.2000.0872

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  8 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Replacement of huntingtin exon 1 by trans-splicing.

Authors:  Hansjörg Rindt; Pei-Fen Yen; Christina N Thebeau; Troy S Peterson; Gary A Weisman; Christian L Lorson
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

3.  Therapeutic Strategies in Huntington's Disease.

Authors:  Ichiro Kanazawa
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

4.  Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.

Authors:  Eileen M Denovan-Wright; Edgardo Rodriguez-Lebron; Alfred S Lewin; Ronald J Mandel
Journal:  Neurobiol Dis       Date:  2007-11-12       Impact factor: 5.996

Review 5.  Antisense therapy in neurology.

Authors:  Joshua J A Lee; Toshifumi Yokota
Journal:  J Pers Med       Date:  2013-08-02

6.  Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.

Authors:  Niels H Skotte; Amber L Southwell; Michael E Østergaard; Jeffrey B Carroll; Simon C Warby; Crystal N Doty; Eugenia Petoukhov; Kuljeet Vaid; Holly Kordasiewicz; Andrew T Watt; Susan M Freier; Gene Hung; Punit P Seth; C Frank Bennett; Eric E Swayze; Michael R Hayden
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

Review 7.  MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?

Authors:  Wissem Deraredj Nadim; Viorel Simion; Helene Benedetti; Chantal Pichon; Patrick Baril; Severine Morisset-Lopez
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

8.  Escins Isolated from Aesculus chinensis Bge. Promote the Autophagic Degradation of Mutant Huntingtin and Inhibit its Induced Apoptosis in HT22 cells.

Authors:  Yueshan Sun; Xueqin Jiang; Rong Pan; Xiaogang Zhou; Dalian Qin; Rui Xiong; Yiling Wang; Wenqiao Qiu; Anguo Wu; Jianming Wu
Journal:  Front Pharmacol       Date:  2020-02-25       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.